Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration

<div>Mean visual acuity (VA) measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts at 4 meters and converted to Snellen over 7 years. (a) Mean change of VA for all eyes. (b) Mean change of VA separated in eyes with good baseline VA ≥ 20/50 (0.7 ETDRS), intermediate VA 20/50–20/114 (0.7–0.35 ETDRS), and minor VA ≤ 20/114 (0.35 ETDRS). (c) Mean change of VA subdivided into three groups based on the average numbers of intravitreal injections per year.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration 

Figure 2 | Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration 